Recent developments, including the May 2026 resignation of prior commissioner Marty Makary and the subsequent acting role of Kyle Diamantas, have kept the FDA commissioner selection process fluid amid ongoing White House interviews with candidates such as Heidi Overton, Jeffrey Vacirca, and Stephen Ferrara. Trader sentiment reflects a fragmented field because no single contender has secured a decisive edge in vetting or alignment with priorities like regulatory modernization and agency leadership stability. Key differentiators include Overton's Domestic Policy Council experience versus Vacirca's oncology network leadership or Ferrara's Pentagon health background, alongside Senate confirmation dynamics and historical patterns of rapid executive branch nominations. Factors that could consolidate support include an imminent formal announcement, committee feedback, or shifts in administration focus before year-end deadlines.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गयास्टीफन हान <1%
काइल डायमांटस <1%
सारा ब्रेनर <1%
31 दिसंबर तक कोई घोषणा नहीं <1%
$33,305 वॉल्यूम
$33,305 वॉल्यूम
30 दिस, 2026
काइल डायमांटस
1%
स्टीफन हान
1%
ब्रेट गिरोइर
<1%
ग्रेस ग्राहम
<1%
सारा ब्रेनर
1%
31 दिसंबर तक कोई घोषणा नहीं
<1%
स्टीफन हान <1%
काइल डायमांटस <1%
सारा ब्रेनर <1%
31 दिसंबर तक कोई घोषणा नहीं <1%
$33,305 वॉल्यूम
$33,305 वॉल्यूम
30 दिस, 2026
काइल डायमांटस
$6,786 वॉल्यूम
1%
स्टीफन हान
$4,144 वॉल्यूम
1%
ब्रेट गिरोइर
$5,265 वॉल्यूम
<1%
ग्रेस ग्राहम
$6,683 वॉल्यूम
<1%
सारा ब्रेनर
$7,418 वॉल्यूम
1%
31 दिसंबर तक कोई घोषणा नहीं
$3,007 वॉल्यूम
<1%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Recent developments, including the May 2026 resignation of prior commissioner Marty Makary and the subsequent acting role of Kyle Diamantas, have kept the FDA commissioner selection process fluid amid ongoing White House interviews with candidates such as Heidi Overton, Jeffrey Vacirca, and Stephen Ferrara. Trader sentiment reflects a fragmented field because no single contender has secured a decisive edge in vetting or alignment with priorities like regulatory modernization and agency leadership stability. Key differentiators include Overton's Domestic Policy Council experience versus Vacirca's oncology network leadership or Ferrara's Pentagon health background, alongside Senate confirmation dynamics and historical patterns of rapid executive branch nominations. Factors that could consolidate support include an imminent formal announcement, committee feedback, or shifts in administration focus before year-end deadlines.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
बाज़ार खुला: May 12, 2026, 7:59 PM ET
वॉल्यूम
$33,305समाप्ति तिथि
31 दिस, 2026बाज़ार खुला
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Recent developments, including the May 2026 resignation of prior commissioner Marty Makary and the subsequent acting role of Kyle Diamantas, have kept the FDA commissioner selection process fluid amid ongoing White House interviews with candidates such as Heidi Overton, Jeffrey Vacirca, and Stephen Ferrara. Trader sentiment reflects a fragmented field because no single contender has secured a decisive edge in vetting or alignment with priorities like regulatory modernization and agency leadership stability. Key differentiators include Overton's Domestic Policy Council experience versus Vacirca's oncology network leadership or Ferrara's Pentagon health background, alongside Senate confirmation dynamics and historical patterns of rapid executive branch nominations. Factors that could consolidate support include an imminent formal announcement, committee feedback, or shifts in administration focus before year-end deadlines.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
वॉल्यूम
$33,305समाप्ति तिथि
31 दिस, 2026बाज़ार खुला
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...Recent developments, including the May 2026 resignation of prior commissioner Marty Makary and the subsequent acting role of Kyle Diamantas, have kept the FDA commissioner selection process fluid amid ongoing White House interviews with candidates such as Heidi Overton, Jeffrey Vacirca, and Stephen Ferrara. Trader sentiment reflects a fragmented field because no single contender has secured a decisive edge in vetting or alignment with priorities like regulatory modernization and agency leadership stability. Key differentiators include Overton's Domestic Policy Council experience versus Vacirca's oncology network leadership or Ferrara's Pentagon health background, alongside Senate confirmation dynamics and historical patterns of rapid executive branch nominations. Factors that could consolidate support include an imminent formal announcement, committee feedback, or shifts in administration focus before year-end deadlines.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया
बाहरी लिंक से सावधान रहें।
बाहरी लिंक से सावधान रहें।
अक्सर पूछे जाने वाले प्रश्न